These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 25354112)

  • 1. Enzalutamide in metastatic prostate cancer before chemotherapy.
    Froehner M; Wirth MP
    N Engl J Med; 2014 Oct; 371(18):1755. PubMed ID: 25354112
    [No Abstract]   [Full Text] [Related]  

  • 2. Further analysis of PREVAIL: enzalutamide use in chemotherapy-naïve men with metastatic castration-resistant prostate cancer.
    Aragon-Ching JB
    Asian J Androl; 2014; 16(6):803-4. PubMed ID: 25080931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enzalutamide in chemo-naïve castration-resistant prostate cancer: effective for most but not for all.
    Maughan BL; Antonarakis ES
    Asian J Androl; 2014; 16(6):807-8. PubMed ID: 25155108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enzalutamide in metastatic prostate cancer before chemotherapy.
    Beer TM; Armstrong AJ; Rathkopf DE; Loriot Y; Sternberg CN; Higano CS; Iversen P; Bhattacharya S; Carles J; Chowdhury S; Davis ID; de Bono JS; Evans CP; Fizazi K; Joshua AM; Kim CS; Kimura G; Mainwaring P; Mansbach H; Miller K; Noonberg SB; Perabo F; Phung D; Saad F; Scher HI; Taplin ME; Venner PM; Tombal B;
    N Engl J Med; 2014 Jul; 371(5):424-33. PubMed ID: 24881730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Global efficacy and clinical application of androgen receptor inhibitors in metastatic prostate cancer.
    Vaishampayan U
    Chin Clin Oncol; 2023 Dec; 12(6):61. PubMed ID: 37691348
    [No Abstract]   [Full Text] [Related]  

  • 6. Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy: additional analyses from the AFFIRM randomized clinical trial.
    Cella D; Ivanescu C; Holmstrom S; Bui CN; Spalding J; Fizazi K
    Ann Oncol; 2015 Jan; 26(1):179-185. PubMed ID: 25361992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance to androgen-pathway drugs in prostate cancer.
    Steinestel J; Schrader AJ; Luedeke M
    N Engl J Med; 2014 Dec; 371(23):2234. PubMed ID: 25470703
    [No Abstract]   [Full Text] [Related]  

  • 8. Enzalutamide after docetaxel and abiraterone acetate treatment in prostate cancer: a pooled analysis of 10 case series.
    Petrelli F; Coinu A; Borgonovo K; Cabiddu M; Ghilardi M; Lonati V; Barni S
    Clin Genitourin Cancer; 2015 Jun; 13(3):193-8. PubMed ID: 25466676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New Treatment Options for Patients With Metastatic Prostate Cancer: What Is The Optimal Sequence?
    van Dodewaard-de Jong JM; Verheul HMW; Bloemendal HJ; de Klerk JMH; Carducci MA; van den Eertwegh AJM
    Clin Genitourin Cancer; 2015 Aug; 13(4):271-279. PubMed ID: 25704270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching and withdrawing hormonal agents for castration-resistant prostate cancer.
    Lorente D; Mateo J; Zafeiriou Z; Smith AD; Sandhu S; Ferraldeschi R; de Bono JS
    Nat Rev Urol; 2015 Jan; 12(1):37-47. PubMed ID: 25563847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-L1 is highly expressed in Enzalutamide resistant prostate cancer.
    Bishop JL; Sio A; Angeles A; Roberts ME; Azad AA; Chi KN; Zoubeidi A
    Oncotarget; 2015 Jan; 6(1):234-42. PubMed ID: 25428917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancer.
    Auchus RJ; Yu MK; Nguyen S; Mundle SD
    Oncologist; 2014 Dec; 19(12):1231-40. PubMed ID: 25361624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enzalutamide for treatment of CRPC: rationale for sequencing and potential clinical biomarker for resistance.
    Lochrin SE; Figg WD; Finn SP
    Cancer Biol Ther; 2015; 16(2):201-3. PubMed ID: 25569176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer.
    Zhang T; Zhu J; George DJ; Armstrong AJ
    Expert Opin Pharmacother; 2015 Mar; 16(4):473-85. PubMed ID: 25534660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance to androgen-pathway drugs in prostate cancer.
    Antonarakis ES; Nakazawa M; Luo J
    N Engl J Med; 2014 Dec; 371(23):2234. PubMed ID: 25470700
    [No Abstract]   [Full Text] [Related]  

  • 16. What is the next generation therapeutic strategy for castration-resistant prostate cancer.
    Wen SM; Quan CY; Jiang N; Shang ZQ; Niu YJ
    Asian J Androl; 2015; 17(2):223-4. PubMed ID: 25432503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate cancer: Enzalutamide--differential cross resistance with taxanes.
    Fenner A
    Nat Rev Urol; 2015 Feb; 12(2):64. PubMed ID: 25534993
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacotherapeutic management of metastatic, castration-resistant prostate cancer in the elderly: focus on non-chemotherapy agents.
    Graff JN; Beer TM
    Drugs Aging; 2014 Dec; 31(12):873-82. PubMed ID: 25387443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can urinary PCA3 supplement PSA in the early detection of prostate cancer?
    Wei JT; Feng Z; Partin AW; Brown E; Thompson I; Sokoll L; Chan DW; Lotan Y; Kibel AS; Busby JE; Bidair M; Lin DW; Taneja SS; Viterbo R; Joon AY; Dahlgren J; Kagan J; Srivastava S; Sanda MG
    J Clin Oncol; 2014 Dec; 32(36):4066-72. PubMed ID: 25385735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AR-V7 predicts prostate cancer treatment response.
    Cancer Discov; 2014 Nov; 4(11):OF1. PubMed ID: 25367950
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.